You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Large B-Cell

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Communication Training Intervention for Large B-Cell Lymphoma

Recruiting
  • Lymphoma, B-Cell
  • +5 more
  • Hematolo-GIST Training
  • Participants Appointment
  • New York, New York
  • +2 more
Jul 3, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Large B-cell Lymphoma Trial (Glofitamab, Polatuzumab vedotin, Obinutuzumab)

Not yet recruiting
  • Large B-cell Lymphoma
  • (no location specified)
Oct 3, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Selinexor Combined With Lenalidomide and Rituximab in Treatment

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • Selinexor combined with lenalidomide and rituximab
  • Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 20, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

    Recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
      • Milan, Italy
        Ospedale San Raffaele
      Aug 29, 2023

      Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)

      Not yet recruiting
      • Relapsed/Refractory Large B-cell Lymphoma
      • (no location specified)
      Oct 6, 2023

      Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

      Recruiting
      • Lymphoma, Non-Hodgkin
      • Diffuse Large B Cell Lymphoma
      • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
      • Tianjin, Tianjin, China
        Tianjin Cancer Hospital
      Nov 19, 2023

      Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

      Not yet recruiting
      • Lymphoma, B-Cell
      • +6 more
      • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
      • Guayaquil, Guayas, Ecuador
        Instituto Oncológico Nacional Dr. Juan Tanca Marengo
      Apr 27, 2023

      Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

      Available
      • Large B-cell Lymphoma
      • +4 more
      • Epcoritamab
      • (no location specified)
      Feb 16, 2023

      CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

      Active, not recruiting
      • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
      • DISEASE
      • (no location specified)
      May 4, 2023

      Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • (no location specified)
      Mar 23, 2023

      Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

      Not yet recruiting
      • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
      • +21 more
      • Biopsy
      • +8 more
      • Columbus, Ohio
        Ohio State University Comprehensive Cancer Center
      Apr 7, 2023